Decorative Decorative

Company Information

Company Profile

Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration. Backed by specialist life science investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with significant clinical and commercial differentiation. Skye plans to launch a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist. SBI-100 Ophthalmic Emulsion, a CB1 agonist, is being studied in a Phase 2 trial of patients with glaucoma and ocular hypertension. Skye expects top-line data from its Phase 2a glaucoma study this quarter.

Latest Presentation

Industry Classifications



Pharmaceutical Preparation Manufacturing (325412)

Pharmaceutical Preparations (2834)

Contact Information

Investor Relations
SKYE Investor Relations
T: (858) 410-0266

Company Contact
Skye Bioscience, Inc.
11250 El Camino Real
Suite 100
San Diego, CA 92130